Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001361284 | SCV001557255 | uncertain significance | Bardet-Biedl syndrome | 2024-10-29 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 856 of the BBS9 protein (p.Val856Leu). This variant is present in population databases (rs764122627, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with BBS9-related conditions. ClinVar contains an entry for this variant (Variation ID: 1053001). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The leucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003284260 | SCV003975288 | uncertain significance | Inborn genetic diseases | 2023-05-03 | criteria provided, single submitter | clinical testing | The c.2566G>T (p.V856L) alteration is located in exon 22 (coding exon 21) of the BBS9 gene. This alteration results from a G to T substitution at nucleotide position 2566, causing the valine (V) at amino acid position 856 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005038127 | SCV005666500 | uncertain significance | Bardet-Biedl syndrome 9 | 2024-01-08 | criteria provided, single submitter | clinical testing |